Viracta Therapeutics, Inc. - Common Stock (NQ:VIRX)

0.0778 UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viracta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 17, 2024

Via Benzinga

Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday? ↗

April 15, 2024

Nanatinostat combined with valganciclovir shows promising results in treating relapsed or refractory EBV+ peripheral T-cell lymphoma, demonstrating higher efficacy and tolerability than nanatinostat...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 12, 2024

Via Benzinga

VIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023 ↗

March 08, 2024

VIRX stock results show that Viracta Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Why Porch Group Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗

March 08, 2024

Shares of Porch Group, Inc. (NASDAQ: PRCH) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance.

Via Benzinga

Viracta Therapeutics: Q3 Earnings Insights ↗

November 09, 2023

Via Benzinga

Expert Ratings for Viracta Therapeutics ↗

August 15, 2023

Via Benzinga

Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

March 08, 2024

Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 08, 2024

Via Benzinga

Viracta Therapeutics Says Pivotal Cancer Trial Achieves Efficacy Threshold For Expansion Into Next Stage ↗

June 28, 2023

Via Benzinga

Analyst Ratings for Viracta Therapeutics ↗

May 10, 2023

Via Benzinga

CACI International To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday ↗

January 05, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 08, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 05, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 17, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

October 05, 2023

On Thursday, 369 companies hit new 52-week lows.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 ↗

July 31, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

May 05, 2023

Friday's session saw 100 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 26, 2023

On Wednesday, 345 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 05, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 14, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

February 27, 2023

Via Benzinga

Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 09, 2023

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.

Via Benzinga

Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket ↗

January 09, 2023

Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

January 09, 2023

We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!

Via InvestorPlace

Stocks That Hit 52-Week Lows On Friday ↗

December 09, 2022

On Friday, 127 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

December 29, 2022

On Thursday, 116 companies set new 52-week lows.

Via Benzinga

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary ↗

September 07, 2022

Via Benzinga

Viracta Obtains Orphan Drug Status From European Commission For T-cell Lymphoma Candidate ↗

September 07, 2022

The European Commission has granted an orphan drug designation (ODD) to Viracta’s (NASDAQ: VIRX) lead drug combination nanatinostat and valganciclovir (Nana-val) for the treatment of peripheral T-cell...

Via Benzinga

5 Value Stocks To Watch In The Healthcare Sector ↗

August 08, 2022

The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.